Hyperprolactinemia. Evaluation and management.
Hyperprolactinemic syndromes are a diverse group of disorders that present in widely different age groups. They are common disorders in both men and women and require management over a lifetime. The past 20 years have greatly increased our knowledge about these disorders and simplified their management. Yet, we have made little progress in understanding the origin and dynamics of pituitary tumors and their natural histories, and as yet we have been unable to develop effective tumoricidal therapy or medication that corrects, at the central axis level, neurotransmitter disorders that may produce hyperprolactinemia. Perhaps these issues will be the subject of such reviews in the future.
Blackwell
R E
RE
Division of Reproductive Biology and Endocrinology, University of Alabama, Birmingham.
D000634:Aminoquinolines / Q000627:therapeutic use; D000818:Animals; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D007246:Infertility / Q000188:drug therapy / Q000209:etiology; D010053:Ovary / Q000502:physiology; D010902:Pituitary Gland / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000628:therapy; D011388:Prolactin / Q000502:physiology; D015175:Prolactinoma / Q000150:complications / Q000628:therapy
D000634:Aminoquinolines; D015259:Dopamine Agents; D001971:Bromocriptine; C046650:quinagolide; D011388:Prolactin